Subscribe: MedWorm: Bladder Cancer
http://www.medworm.com/rss/medicalfeeds/cancers/Bladder-Cancer.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
bladder cancer  bladder  cancer  cystectomy  journal urology  journal  radical cystectomy  source journal  source  urology 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Bladder Cancer

MedWorm: Bladder Cancer



MedWorm.com provides a medical RSS filtering service. Over 7000 RSS medical sources are combined and output via different filters. This feed contains the latest news and research in the Bladder Cancer category.



Last Build Date: Tue, 29 Mar 2016 16:50:23 +0100

 



Mp38-20 simplified clinical comorbidity index for patients candidate to radical cystectomy

Mon, 28 Mar 2016 19:24:11 +0100

Several variables used in the definition of the Charlson comorbidity index (CCI) may not be applicable in contemporary patients candidate to radical cystectomy-RC- (i.e. severe liver disease, dementia, hemiplegia or paraplegia, AIDS) and others may have limited discriminant abilities. We attempted to identify the most informative predictors of perioperative mortality, in RC candidates, within the 17 original groupings of comorbid conditions that are used to quantify the Deyo implementation of CCI. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp38-19 readaptation of the peritoneum following extended pelvic lymph node dissection (plnd) and cystectomy has beneficial impact on bowel function in the long term without compromising oncological radicality.

Mon, 28 Mar 2016 19:24:11 +0100

Decrease in postoperative pain and earlier recovery of bowel function were achieved in patients after readaptation of the peritoneum following extended PLND and cystectomy. The aim of our study was to evaluate oncological outcomes and bowel function in the long term. (Source: The Journal of Urology)



Mp38-18 urethral recurrence after radical cystectomy: revisiting the incidence and predictors in a large contemporary series

Mon, 28 Mar 2016 19:24:11 +0100

There is paucity of data about the incidence and predictors of urethral recurrence after radical cystectomy. We opt to identify risk factors of urethral recurrence stratified by gender in a large contemporary series. In addition, sub-analysis for male patients underwent orthotopic bladder substitution (OBS) was performed to determine the risk of urethral recurrence and potential urinary conversion. (Source: The Journal of Urology)



Mp38-17 attempted nerve sparing has a long term impact on urinary continence in patients with an orthotopic bladder substitute

Mon, 28 Mar 2016 19:24:11 +0100

The value of nerve sparing (NS) in order to improve functional outcomes after diversion with an orthotopic bladder substitute (OBS) remains a matter of debate. The purpose of this study was to analyze voiding patterns of long-term survivors. (Source: The Journal of Urology)



Mp38-16 outcomes of robot-assisted repair of diversion-related complications after robot-assisted radical cystectomy

Mon, 28 Mar 2016 19:24:11 +0100

We reported our 10-year experience of robot-assisted repairs of diversion-related complications (Source: The Journal of Urology)



Mp38-15 extracapsular extension and lymph node density in urothelial carcinoma of the bladder following radical cystectomy in nodal-positive patients

Mon, 28 Mar 2016 19:24:11 +0100

Patients with lymph node metastases (LNM) suffer from an impaired outcome after radical cystectomy for urothelial carcinoma of the bladder (UCB). Lymph node density (LND) and extracapsular extension (ECE) are debated as independent predictors in nodal-positive patients. However, neither LND nor ECE have been established as a prognostic marker in daily clinical practice. Thus, the aim of the current study was to evaluate the prognostic value of LND and ECE based on the data from the Prospective Multicenter Radical Cystectomy Series 2011 (PROMETRICS 2011) in patients with LNM. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp38-14 implementing a multimodal prehabilitation program in a high-volume bladder cancer center

Mon, 28 Mar 2016 19:24:11 +0100

Radical Cystectomy (RC) is followed by a significant postoperative morbidity and complications. Enhancing an individual’s functional capacity and nutritional status before scheduled surgery; aimed at improving the patient’s tolerance to upcoming physiological stress, has been defined as prehabilitation. Evidence suggests that the preoperative period may be an opportune time to intervene and proactively involve the patients in own recovery. Thus, a higher level of implementation and experience in clinical practice of the current established evidence is warranted to secure an optimal pathway. (Source: The Journal of Urology)



Mp38-13 long-term 10-year health-related quality of life outcomes following radical cystectomy

Mon, 28 Mar 2016 19:24:11 +0100

Ileal conduit (IC), neobladder (NB) and Indiana pouch (IP) urinary diversions (UD) are offered after radical cystectomy (RC). Current literature has conflicting and inconclusive results regarding a superior diversion. We evaluate long-term (>10 years) health-related quality of life (HRQOL) outcomes following radical cystectomy, comparing IC, NB and IP. (Source: The Journal of Urology)



Mp38-12 prophylactic antibiotics in the first 30 days following radical cystectomy with urinary diversion leads to fewer urinary tract infections

Mon, 28 Mar 2016 19:24:11 +0100

Urinary tract infections and sepsis from a urinary source contribute significantly to the morbidity associated with cystectomy and urinary diversion. Many of these urinary tract infections and readmissions for urosepsis occur in the first 30 days following surgery and around the time of ureteral stent removal. The purpose of this study was to determine if prophylactic antibiotics decreases urinary tract infections in the first 30 days following radical cystectomy. (Source: The Journal of Urology)



Mp38-11 oncological trifecta and pentafecta criteria in a contemporary cohort of bladder cancer patients after radical cystectomy

Mon, 28 Mar 2016 19:24:11 +0100

To assess the rate and readily available preoperative predictors of trifecta and pentafecta criteria in bladder cancer (BCa) patients that underwent radical cystectomy (RC). The criteria were taken from a recent expert survey. (Source: The Journal of Urology)



Mp38-10 cystectomy associated with improved overall survival in very elderly patients with muscle invasive bladder cancer; results from the national cancer data base

Mon, 28 Mar 2016 19:24:11 +0100

Cystectomy offers a survival advantage for muscle invasive bladder cancer (MIBC), but it is unclear if the very elderly receive this benefit given the competing risks of death, and morbidity of major surgical intervention in this population. We sought to assess overall survival (OS) in elderly patients with MIBC by treatment type. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp38-09 does the ileal length used for neobladder reconstruction after radical cystectomy impact on postoperative bowel habits ? - a comparison between the studer- and the i-pouch

Mon, 28 Mar 2016 19:24:11 +0100

The aim of the study was to investigate whether the length of ileum used for neobladder reconstruction after radical cystectomy (RC) for bladder cancer (60cm vs. 40cm) impacts on postoperative bowel function. (Source: The Journal of Urology)



Mp38-08 prognostics factors of positives ureteral section during cystectomy for bladder cancer.

Mon, 28 Mar 2016 19:24:11 +0100

radical cystectomy is the standard treatment for muscle invasive bladder cancer. Analysis of ureterals sections ensures intraoperative or postoperative no residual carcinoma of the urinary tract. There are no specific recommendations on prognostics factors of positive ureteral section justifying the frozen section. Objectives: Identify the prognostic factors of tumor reached ureteral section. To evaluate the sensitivity and specificity of frozen section during radical cystectomy. (Source: The Journal of Urology)



Mp38-07 measuring the depth of tumor invasion may have greater prognostic value than ajcc/uicc staging of bladder cancer.

Mon, 28 Mar 2016 19:24:11 +0100

AJCC/UICC staging system is the gold standard to predict patient outcomes. However, many studies report that pT staging (pT2 vs. pT3) may not be a useful prognostic factor. In addition, a recent study showed that pathological criteria of distinction between pT2 and pT3 are variable among pathologists. (Source: The Journal of Urology)



Mp38-06 comparing long-term oncologic outcomes between open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial

Mon, 28 Mar 2016 19:24:11 +0100

In a randomized trial comparing robot-assisted laproscopic radical cystectomy (RARC) to open radical cystectomy (ORC), we excluded the possibility of large differences in 90-day perioperative outcomes. There is a paucity of long-term oncologic outcomes comparing RARC and ORC and are limited to retrospective reports. Herein, we report the outcomes from a prospective, randomized clinical trial comparing RARC and ORC. (Source: The Journal of Urology)



Mp38-05 tumor dissemination during robot-assisted radical cystectomy: does the emperor have no clothes?

Mon, 28 Mar 2016 19:24:11 +0100

Local recurrence remains a major cause of cancer-specific mortality following radical cystectomy. We sought to investigate tumor dissemination in the operative field and contribution of pneumoperitoneum during robot-assisted radical cystectomy (RARC). (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp38-04 survival, perioperative outcomes, and costs after robotic-assisted versus open radical cystectomy: a national comparative effectiveness study

Mon, 28 Mar 2016 19:24:11 +0100

Radical cystectomy is the gold-standard management for muscle-invasive bladder cancer, and there is debate concerning the comparative effectiveness of robotic-assisted (RARC) versus open radical cystectomy (ORC). We sought to compare utilization, perioperative, cost and survival outcomes of RARC versus ORC. (Source: The Journal of Urology)



Mp38-03 an easily applicable mortality index for patients selected for radical cystectomy or radical prostatectomy

Mon, 28 Mar 2016 19:24:11 +0100

To determine which single comorbid conditions are independently associated with competing mortality after radical cystectomy or radical prostatectomy in order to develop a mortality index. (Source: The Journal of Urology)



Mp38-02 the amount of intra- and postoperative blood transfusion in bladder cancer patients with radical cystectomy is an independent prognostic factor for poor outcome – results of a single-center study

Mon, 28 Mar 2016 19:24:11 +0100

In this study we analyzed the influence of intra- and postoperative BT on cancer-specific survival (CSS) in patients with UCB that had RC. (Source: The Journal of Urology)



Mp38-01 the association of variant histology and extra nodal extension in node positive urothelial carcinoma of the bladder

Mon, 28 Mar 2016 19:24:11 +0100

Extra nodal extension (ENE) is associated with poor outcomes in lymph node (LN) positive bladder cancer patients treated with radical cystectomy (RC). In addition, variant histologies of urothelial carcinoma of the bladder (UCB) seem to be associated with unfavorable outcomes after RC. The impact of variant UCB histologies on ENE, however, remains unclear. To investigate the association of variant UCB histologies and ENE as well as their predictive value on outcomes. (Source: The Journal of Urology)



Fri-05 the rise and fall of occupational bladder cancer in the western world

Mon, 28 Mar 2016 19:24:11 +0100

This study reviews the milestones that lead to the discovery of carcinogens and the changes in employment regulations that lead to a fall in occupational bladder cancer. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp49-20 ex vivo fluorescence imaging of urothelial carcinoma in human bladders targeted by icg-phlip

Mon, 28 Mar 2016 19:24:10 +0100

Early detection of bladder cancer increases the chances of successful treatment and bladder function preservation. We employed pH Low Insertion Peptide (pHLIP), which targets cells with low extracellular pH in tumors, to visualize cancerous lesions in human bladder specimens. (Source: The Journal of Urology)



Mp49-19 comparative evaluation of health related quality of life (hrqol) instruments for bladder cancer.

Mon, 28 Mar 2016 19:24:10 +0100

Orthotopic neobladder (ON) and ileal conduit (IC) are common urinary diversions performed after radical cystectomy (RC) for bladder cancer. Previous HRQOL studies in cystectomy patients have yielded conflicting results. Using a cross sectional study design we examined the only two validated Bladder Cancer Specific HRQOL (BCSHRQOL) measures. A third instrument, the EORTC-QLQ-BLM30 was excluded as it had not been explicitly validated at the time of study initiation. The aim of this study was to determine if we would find similar results using different BCSHRQOL instruments in the same patient population. (Source: The Journal of Urology)



Mp49-18 fdg pet-ct vs ct scan in the staging of urothelial neoplasms

Mon, 28 Mar 2016 19:24:10 +0100

Thoracic and abdominal CT scan remains the gold standard for staging of urothelial carcinoma. No prospective trials have adequately assessed the role of FDG PET-CT. (Source: The Journal of Urology)



Mp49-17 clinical outcomes of patients with histologic variants of bladder cancer treated with trimodal bladder-sparing therapy

Mon, 28 Mar 2016 19:24:10 +0100

The clinical outcomes of patients with histologic variants of muscle invasive bladder cancer (MIBC) treated with radical cystectomy is an emerging topic. While trimodal bladder-sparing therapy (TMT) is an acceptable treatment for selected patients with MIBC, the outcomes of TMT in histologic variants remains largely unknown. To our knowledge, we present the largest series of urothelial histologic variants treated with TMT. (Source: The Journal of Urology)



Mp49-16 factors predicting failure to follow pre-scheduled gemcitabine plus cisplatin chemotherapy regimen for urothelial carcinoma

Mon, 28 Mar 2016 19:24:10 +0100

Gemcitabine plus cisplatin (GC) chemotherapy is a gold standard chemotherapeutic regimen for metastatic or advanced urothelial carcinoma. However, because of its hematologic toxicity, a proportion of the patients cannot receive scheduled gemcitabine administration on Day8 and/or Day15. Incomplete GC regimen may lead disease progression, especially in the neoadjuvant setting. Thus, in the present study, we aimed to identify factors associated with incompletion of GC chemotherapy. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp49-15 clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy

Mon, 28 Mar 2016 19:24:10 +0100

In bladder cancer, neoadjuvant chemotherapy (NAC) can downstage the primary tumor prior to radical cystectomy (RC), and may impact eventual overall survival. However, the optimal management in patients with persistent non-organ confined disease (pT3-4 and/or pN+) following RC is unknown. The aim of this study was to describe use and outcomes of adjuvant chemotherapy (ACT) in patients with residual non-organ confined cancer following NAC and RC. (Source: The Journal of Urology)



Mp49-14 predictive value of radiological response rate for pathological response to neoadjuvant chemotherapy and post-cystectomy survival of bladder urothelial cancer

Mon, 28 Mar 2016 19:24:10 +0100

For non-metastatic muscle-invasive bladder cancer (MIBC), radical cystectomy (RC) following neoadjuvant systemic chemotherapy (NAC) is recommended. Pathological response to NAC was reported to be strongly associated with post-RC oncological outcomes. However, there has been a few reports on the preoperative predictors for pathological response to NAC. The purpose of this study is to determine predictive value of radiological response rate assessed by serial pelvic CT scans for pathological response to NAC and clinical outcomes after RC in MIBC patients. (Source: The Journal of Urology)



Mp49-13 selective neoadjuvant chemotherapy by prediction systems improves the chemo-sensitivity of the muscle invasive bladder cancers

Mon, 28 Mar 2016 19:24:10 +0100

To compare the rate of chemo-sensitivity in neoadjuvant chemotherapy for muscle invasive bladder cancer between historical control and this interventional prospective study by using our M-VAC and CaG prediction systems. (Source: The Journal of Urology)



Mp49-12 neoadjuvant chemotherapy for invasive bladder cancer: is it right for everyone?

Mon, 28 Mar 2016 19:24:10 +0100

Neoadjuvant chemotherapy (NAC) has been shown to improve survival of patients with muscle invasive bladder cancer (MIBC). NAC is thought to treat systemic micro-metastatic disease prior to definitive radical cystectomy (RC). However, the impact of NAC on pathologic lymph node (LN) status in patients with clinically negative LNs is unknown. We studied the effect of NAC on LN status for patients with MIBC and cN0. (Source: The Journal of Urology)



Mp49-11 neoadjuvant gemcitabine and carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy: a propensity score-matched analysis

Mon, 28 Mar 2016 19:24:10 +0100

Standard neoadjuvant chemotherapy has not yet been established for patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin (CDDP)-based chemotherapy. We conducted a propensity score analysis to evaluate the clinical significance of neoadjuvant gemcitabine and carboplatin (GCarbo) chemotherapy for CDDP-ineligible patients with MIBC. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp49-10 perioperative and oncological outcomes of obese patients with bladder cancer undergoing robotic assisted radical cystectomy

Mon, 28 Mar 2016 19:24:10 +0100

Obesity has been shown to pose greater perioperative risks including longer operative time, higher blood loss and increased post-operative complication rates in patients undergoing radical cystectomy. Obesity has also been associated with worse oncological outcomes. Robotic assisted radical cystectomy (RARC) may have an advantageous effect in improving the perioperative outcomes including complication rates and length of stay. (Source: The Journal of Urology)



Mp49-09 improved outcome with adjuvant chemotherapy in locally advanced or lymph node positive tumors after radical cystectomy

Mon, 28 Mar 2016 19:24:10 +0100

Adding chemotherapy to radical cystectomy may improve outcome. Neoadjuvant treatment is advocated by guidelines based on meta-analysis data but is underused in clinical practice. Adjuvant treatment of risk patients could be an alternative. We analyzed the effect of adjuvant chemotherapy given to risk patients in a single center routine clinical setting. (Source: The Journal of Urology)



Mp49-08 prognostic significance of depth of invasion in transurethral resection of bladder tumor specimens.

Mon, 28 Mar 2016 19:24:10 +0100

Depth of invasion in transurethral resection of bladder (TURB) biopsies of T1 urothelial cancer has previously been evaluated for subclassification. This has been done by measuring depth of lamina propria (LP) invasion or by identifying muscularis mucosa invasion, however these are affected by tissue orientation, LP variation, and inconclusive presence of muscularis mucosa. Identifying tumor that is adjacent to detrusor muscle (TADM) is not affected by orientation or LP size and may be a better histologic indicator of advanced T1 disease. (Source: The Journal of Urology)



Mp49-07 the risk of postoperative venous thromboembolism according to the circulating tumor cell status in patients with urothelial carcinoma of the bladder treated with radical cystectomy

Mon, 28 Mar 2016 19:24:10 +0100

Urothelial carcinoma of the bladder (UCB) patients are at a relevant risk for venous thromboembolism (VTE) following radical cystectomy (RC). In other cancer entities, circulating tumor cells (CTC) are associated with an increased risk of VTE. To evaluate whether the presence of CTC is associated with an increased postoperative risk of VTE and surgical complications in UCB patients treated with RC. (Source: The Journal of Urology)



Mp49-06 assessing cancer progression and stable disease after neoadjuvant chemotherapy for muscle-invasive bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

This study was designed to evaluate pNR to NAC to better risk stratify these patients. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp49-05 prognostic impact of c-reactive protein kinetics on survival of patients with advanced urothelial carcinoma

Mon, 28 Mar 2016 19:24:10 +0100

Pretreatment C-reactive protein (CRP) levels are prognostic for various stages of urothelial carcinoma. To demonstrate that dynamic changes in serum CRP would be a useful biomarker for advanced urothelial carcinoma (aUC), we evaluated the impact of CRP kinetics on patient survival. (Source: The Journal of Urology)



Mp49-04 the utility of neutrophil-to-lymphocyte ratio in determining survival outcomes in patients treated with neoadjuvant chemotherapy and radical cystectomy for high-risk bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

Pre-operative Neutrophil-to-lymphocyte ratio (NLR) has been found to be associated with adverse pathological results and poor long-term outcomes in patients treated with radical cystectomy (RC) for urothelial carcinoma (UC). Prior studies had either a very limited sample size of patients who received neoadjuvent chemotherapy or excluded them from evaluation. We aimed to evaluate the predictive utility of NLR in patients treated with neoadjuvant chemotherapy (NAC) and RC for high-risk UC. (Source: The Journal of Urology)



Mp49-03 comparative effectiveness of robot-assisted and open radical cystectomy: cancer control

Mon, 28 Mar 2016 19:24:10 +0100

Robot-assisted radical cystectomy (RARC) represents an emerging treatment option in patients with bladder cancer (BCa). The aim of our study was to compare the oncologic outcomes of RARC and open radical cystectomy (ORC) in two high-volume centers. (Source: The Journal of Urology)



Mp49-02 a study to evaluate the prognostic and predictive utility of ccp and hrd assays and genetic sequencing in patients undergoing neoadjuvant chemotherapy in bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

In an effort to identify potential biomarkers in urothelial bladder cancer (UBC) that will aid in characterizing disease aggressiveness and/or predict cisplatin chemo-sensitivity, we explored the utility of a combination of nucleic acid-based assays. (Source: The Journal of Urology)



Mp49-01 next generation sequencing of cell free dna reveals genomic aberrations in metastatic urothelial carcinoma

Mon, 28 Mar 2016 19:24:10 +0100

To date, only limited data is available on genomic alterations present in metastatic lesions of patients with metastatic urothelial carcinoma (mUC). The constant release of circulating cell free DNA (cfDNA) from tumor cells into the peripheral blood stream may provide a valuable source for detection of cancer associated somatic copy number variations and mutations. The value of next-generation sequencing (NGS) of cfDNA to identify unknown genomic mutations in patients with bladder cancer has not been addressed. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Pd27-12 primary analysis of imvigor 210: atezolizumab in platinum-treated advanced urothelial carcinoma

Mon, 28 Mar 2016 19:24:10 +0100

Advanced urothelial carcinoma (UC) has few therapeutic options characterized by poor response rates (RR) and significant toxicity. Atezolizumab (atezo; anti-programmed death-ligand 1 [PD-L1]; MPDL3280A) was designed to reinvigorate antitumor immunity. Based on promising Phase (Ph) 1a data, this Ph 2 trial was conducted in advanced or metastatic UC (mUC) pts. (Source: The Journal of Urology)



Pd27-11 parastomal hernia after ileal conduit urinary diversion: re-visiting the predictors radiologically and according to patient reported outcome measures

Mon, 28 Mar 2016 19:24:10 +0100

Parastomal hernia (PSH) is a devastating complication after ileal conduit urinary diversion. Previous studies have explained predictors based on radiological evidence of the hernia regardless the grade and patient reported outcome measures (PROM). The aim of this study is to re-evaluate the predictors based on a standard grading methodology and according to PROM. (Source: The Journal of Urology)



Pd27-10 long-term survivors with an ileal orthotopic bladder substitute maintain good continence and renal function outcomes

Mon, 28 Mar 2016 19:24:10 +0100

We report on our institutional series of OBS pts who were followed ≥10 yrs. (Source: The Journal of Urology)



Pd27-09 incidence and significance of thrombo-embolic events in bladder urothelial carcinoma patients undergoing neo-adjuvant chemotherapy and radical cystectomy: results from multi-centre north-american and european contemporary data

Mon, 28 Mar 2016 19:24:10 +0100

The objectives of this study were to investigate the incidence and characteristics of TEE during and after NAC and subsequent RC for urothelial bladder cancer. (Source: The Journal of Urology)



Pd27-08 exercise-based prehabilitation is feasible and effective in radical cystectomy pathways - secondary results from a randomized controlled trial

Mon, 28 Mar 2016 19:24:10 +0100

Physical exercises offer a variety of health benefits to cancer survivors during and post-treatment. However, exercise-based pre-habilitation is not well reported in major uro-oncology surgery. The aim of this study was to investigate the feasibility, the adherence and the efficacy of a short-term physical pre-habilitation program for patients with invasive bladder cancer awaiting radical cystectomy (RC). (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Pd27-07 bladder-sparing protocol consisting of low-dose chemoradiotherapy and consolidative partial cystectomy against muscle-invasive bladder cancer: comparison of oncological and functional outcomes between older and younger patients

Mon, 28 Mar 2016 19:24:10 +0100

We evaluated oncological and functional outcomes of muscle-invasive bladder cancer (MIBC) treatment with our bladder-sparing protocol consisting of transurethral resection of bladder tumor (TURB), low-dose chemoradiotherapy (LCRT), and consolidative partial cystectomy (PC) (Urol Oncol 2013, BJU Int 2012, 2009), comparing outcomes in elderly and younger patients. (Source: The Journal of Urology)



Pd27-06 the impact of cigarette smoking and smoking cessation on oncological aggressiveness at radical cystectomy – a prospective, european, multicenter study of the eau young academic urologists (yau) bladder cancer working group

Mon, 28 Mar 2016 19:24:10 +0100

Cigarette smoking is the best established, individually controllable risk factor for development of urothelial carcinoma of the bladder (UCB). Retrospective studies suggest a relationship of active smoking status, as well as increasing amount and duration with an augmented risk of unfavorable tumor biologic features and oncological outcomes in patients treated with radical cystectomy (RC). In contrast, smoking cessation seems to abrogate the risk. The aim of this study was to evaluate these associations in a contemporary, prospective, multicenter study. (Source: The Journal of Urology)



Pd27-05 increased cystectomy utilization in the very elderly without compromising perioperative outcomes: results from the national cancer data base

Mon, 28 Mar 2016 19:24:10 +0100

Bladder cancer is often diagnosed in elderly patients with significant comorbidity and competing risks of death. The best treatment approach for muscle-invasive bladder cancer (MIBC) in the very elderly can be a challenge, weighing effectiveness and morbidity. We sought to assess nationwide cystectomy utilization patterns and perioperative outcomes in the very elderly with localized MIBC. (Source: The Journal of Urology)



Pd27-04 development, validation & clinical application of an intra-operative assessment of completion & appropriateness of lnd after radical cystectomy: pelvic lymphadenectomy appropriateness & completion evaluation (place)

Mon, 28 Mar 2016 19:24:10 +0100

Consensus exists on performing a Lymph Node Dissection (LND) after Radical Cystectomy (RC), although its extent and yield are both variable. The final operative view of the surgical field after completion of LND is the best quality measure of a thorough LND. We sought to develop a scoring tool to determine the intraoperative completeness and appropriateness of a LND after RC. (Source: The Journal of Urology)



Pd27-03 oncologic surveillance following radical cystectomy: an individualized risk-based approach.

Mon, 28 Mar 2016 19:24:10 +0100

The appropriate duration of surveillance for bladder cancer (BC) following radical cystectomy (RC) remains unknown. Uniform adherence to current guidelines has the potential for over utilization of resources in some patients and deficiency of testing in others. Herein, we provide an approach to surveillance which balances the risk of recurrence versus the risk of non-BC death. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Pd27-02 composite quality score based analysis of 425 robot-assisted radical cystectomies: evaluation of a decade of experience

Mon, 28 Mar 2016 19:24:10 +0100

We sought to develop a Composite Score to assess the quality of operative care provided for our patients who received robot-assisted radical cystectomy (RARC) over a decade (Source: The Journal of Urology)



Pd27-01 contemporary utilization trends and survival outcomes in patients undergoing radical cystectomy and bladder preservation therapy for muscle invasive bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

To compare overall survival (OS) in patients undergoing radical cystectomy (RC) and bladder preservation therapy (BPT) for muscle invasive urothelial carcinoma of the bladder. (Source: The Journal of Urology)



Mp46-10 evaluating the cost-effectiveness of surveillance schedules for recurrence in low-risk bladder cancer patients

Mon, 28 Mar 2016 19:24:10 +0100

Non-muscle invasive urothelial carcinoma (NMI-UC) is a disease characterized by high recurrence rates which may progress into aggressive muscle invasive bladder cancer. Therefore surveillance of these patients is warranted. Current guidelines are discordant on the optimal surveillance schedule. Our objective was to estimate the cost-effectiveness of different surveillance schedules across different age groups. (Source: The Journal of Urology)



Mp46-07 cost-effectiveness of extended venous thromboembolism prophylaxis after radical cystectomy

Mon, 28 Mar 2016 19:24:10 +0100

While radical cystectomy is the gold standard therapy for muscle-invasive bladder cancer, perioperative complications occur frequently. Venous thromboembolism (VTE), pulmonary embolism and deep vein thrombosis are among the most dreaded complications, with some series reporting >12% incidence with inpatient-only prophylaxis (IPO). Although extended VTE prophylaxis (VTEP) using 21 to 30 days of enoxaparin following discharge has been demonstrated to be effective in surgical oncology and orthopedics, increased postoperative bleeding risk must be accepted. (Source: The Journal of Urology)



Mp45-20 rasal2, a novel ras gtpase activating protein, inhibits stemness and epithelial-mesenchymal transition via mapk/sox2 pathway in bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

Patients with bladder cancer (BCa) have high incidence of relapse and metastasis. Unfortunately, the molecular mechanism of these processes remains poorly understood. In our study, we demonstrate RASAL2, a novel RAS GTPase activating protein (RASGAP), is a suppressor in BCa, which modulates cancer stemness and epithelial-mesenchymal transition (EMT) contributing to relapse and metastasis of BCa. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp45-19 bruce bridges autophagy and apoptosis in silibinin-induced cell death in bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

Autophagy is a tightly-regulated catabolic process that involves the degradation of intracellular components via lysosomes. Although the pivotal role of autophagy in cell growth, development, and homeostasis has been well understood, its function in bladder cancer (BCa) prevention and intervention remains to be delineated. We previously identified intravesical silibinin, a natural flavonoid, as a novel and effective chemopreventive therapy against BCa, which were associated with its proapoptotic effects. (Source: The Journal of Urology)



Mp45-18 a potential role for 6-sulfo sialyl lewisx in metastasis of bladder urothelial carcinoma

Mon, 28 Mar 2016 19:24:10 +0100

It is widely accepted that sialyl Lewis X(sLeX) and sialyl Lewis A(sLeA, also known as CA19-9) glycans expressed on cancer cells function in E-selectin-mediated metastasis. Recently, it was reported that 6-sulfo sLeX glycans detected by the MECA-79 monoclonal antibody are expressed in roughly a quarter of gastric adenocarcinoma cases, and that these cases show a poorer prognosis than MECA-79-negative cases do. The present study was undertaken to assess expression of 6-sulfo sLeX glycans in bladder urothelial carcinoma and evaluate potential clinical implications. (Source: The Journal of Urology)



Mp45-17 clinical significance of pd-l1 protein expression and tumor infiltrating lymphocytes in early stage urothelial bladder carcinomas

Mon, 28 Mar 2016 19:24:10 +0100

Cancer immunotherapy with monoclonal antibodies targeting the PD-1/PD-L1 axis induces prominent and lasting clinical responses in patients with diverse tumor types. In bladder cancer (BC), the PD-1 blocking antibody pembrolizumab and the anti PD-L1 antibody atezolizumab have shown unprecedented clinical benefit in patients with metastatic disease. Expression of PD-L1 and elevated tumor infiltrating lymphocytes (TILs) has been consistently associated with response to PD-1 axis blockers in advanced solid tumors. (Source: The Journal of Urology)



Mp45-16 radical cystectomy and urinary diversion lead to metabolic acidosis and increased bone turnover which persists at least one year after surgery

Mon, 28 Mar 2016 19:24:10 +0100

Intestinal urinary diversion results in development of chronic metabolic acidosis (CMA). CMA results in osteoclast activation, loss of bone calcium, and loss of collagen matrix, which may lead to increased risk of fractures. The effect of urinary diversion on bone turnover markers has not been studied. Serum N-terminal type 1 procollagen (P1NP) and collagen type 1 cross-linked C-telopeptide (CTX) are markers of bone formation (ostetoblast activity) and bone resorption (osteoclast activity), respectively. (Source: The Journal of Urology)



Mp45-15 non-invasive urothelial cancer biomarkers

Mon, 28 Mar 2016 19:24:10 +0100

The current gold standard diagnostic method of urothelial cancers including bladder, ureter and renal pelvis cancers is cystoscopy and urine cytology. Considering the invasiveness and diagnostic performance of the method as well as the highly recurrent nature of urothelial cancers, new non-invasive biomarkers with higher sensitivity are in need. Exosomes and microvesicles (EMV) are released into urine from all the area of nephrons, therefore considered as a promising biomarker source for kidney diseases. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp45-14 epigenetic regulation of candidate tumor suppressor gene adamts18 in human bladder cancer associated with its prognosis

Mon, 28 Mar 2016 19:24:10 +0100

A disintegrin and metalloproteinase with thrombospondin motifs 18 (ADAMTS18), located on 16p23.1, is involved in carcinogenesis of multiple cancers, but its role in bladder cancer (BCa) remains unclear. Here, we reported the epigenetic alterations of ADAMTS18 and its function in bladder carcinogenesis. (Source: The Journal of Urology)



Mp45-13 centrosome amplification as a putative prognostic biomarker for improved objective classification of urothelial carcinoma

Mon, 28 Mar 2016 19:24:10 +0100

Recent studies have reported that centrosome amplification (CA) is closely related to chromosomal instability (CIN) and patient prognosis in human malignancies. The relationship between DNA copy number aberrations (DCNAs) and CA remains to be elucidated. Therefore we examined the relationship between CA and genomic alterations in urothelial carcinomas. To our knowledge, this is the first report to confirm CA as a reliable biomarker for assessing DCNAs in urothelial carcinomas. (Source: The Journal of Urology)



Mp45-12 prognostic value of dna damage response related proteins in non-muscle invasive bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

Non muscle-invasive bladder cancer (NMIBC) is characterized by a high risk of recurrence after transurethral resection (Five-year recurrence rate is 31-78%). Several biomarkers have been studied as a recurrence prognostic tool, being p53 the most widely investigated. P53 is a tumor suppressor that plays an important role in DNA damage response (DDR), being up regulated by a network of proteins such as ATM or Chk2 and their activated forms (phosphorylated). (Source: The Journal of Urology)



Mp45-11 prognostic impact of perioperative lymphocyte-monocyte ratio in patients with bladder cancer undergoing radical cystectomy

Mon, 28 Mar 2016 19:24:10 +0100

Various systemic inflammatory response biomarkers are associated with oncological outcome. We evaluated the superiority of prognostic predictive accuracy between neutrophil-lymphocyte ratio (NLR) and lymphocyte-monocyte ratio (LMR), and the prognostic significance of their perioperative change in patients with bladder cancer undergoing radical cystectomy (RC). (Source: The Journal of Urology)



Mp45-10 identification of downstream genes of the mtor pathway that predict recurrence and progression in non-muscle invasive high-grade urothelial carcinoma of the bladder

Mon, 28 Mar 2016 19:24:10 +0100

We aimed to identify the downstream genes of the mammalian target of rapamycin (mTOR) pathway that could be used to overcome cross-talk and to predict recurrence and progression in non-muscle invasive high-grade urothelial carcinoma (HG-URCa) of the bladder. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp45-09 circulating tumor cells (ctc) identification in bladder cancer using epcam (epithelial cell adhesion molecule): comparison between manual and automated system of isolation and future prospective

Mon, 28 Mar 2016 19:24:10 +0100

Even if high-risk NMIBC is considered a non-invasive tumor the risk of recurrence is up to 78% while the risk of progression is up to 45%. CTC, released in circulation in an early phase of cancer disease, may improve prognostication. Many CTC isolation systems have been developed and mainly they use EpCAM (epithelial cell adhesion molecule) as target of monoclonal antibodies. CELLectionTM Dynabeads using a manual approach allow to identify and to characterize CTCs while CellSearch using an automated system allow identification and counting. (Source: The Journal of Urology)



Mp45-08 stabilization of invadopodia by plectin- mediated conjunction to vimentin intermediate filament is a critical molecular step of invasion and extravasation for metastasis in bladder cancer.

Mon, 28 Mar 2016 19:24:10 +0100

To investigate the molecular mechanisms of bladder cancer (BCa) metastasis, we previously isolated a high-metastatic BCa cell subpopulation from a low-metastatic cell line by using an in vivo selection system (Sugiyama et al Oncol. Res. 20, 289-295). The high-metastatic BCa cell subpopulation showed a high ability to form invadopodia, the filamentous (F-) actin-based membrane protrusions that play an essential role in cancer cell invasion. Analysis of gene expression profiles revealed that the expression of an intermediate filament (IF) protein, vimentin and a cytoskeletal linker protein, plectin was up-regulated in the high-metastatic BCa cells compared with the low-metastatic BCa cell line. (Source: The Journal of Urology)



Mp45-07 advanced two-step transcriptional amplification as a novel system for detecting viable bladder cancer cells

Mon, 28 Mar 2016 19:24:10 +0100

The two-step transcriptional amplification (TSTA) system was previously reported to enhance the tissue-specific gene expression driven by weak promoters, but the enhancement of the gene expression is limited to use in in vitro and in vivo experimental situations. (Source: The Journal of Urology)



Mp45-06 clinical significance and biological roles of rab23 in human bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

Rab23 overexpression has been implicated in several human cancers, but not in bladder cancer. In the present study, we investigated its expression pattern and biological roles in human bladder cancer. (Source: The Journal of Urology)



Mp45-05 urothelium-specific and temporally controlled bi-allelic inactivation of both pten and p53 triggers basal-subtype muscle-invasive bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

Recent whole-genome analyses demonstrated that the activation of receptor tyrosine kinase (RTK)/RAS/PI3K pathway and the inactivation of p19/MDM2/p53 pathway occur in 72% and 76%, respectively, of human muscle-invasive bladder cancer (MIBC). Whether these two events merely represent genetic drifting or are causative of MIBC remains unclear and is the subject of the present study. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp45-04 paternally expressed gene-10 promotes cell growth and invasion of bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

We have recently identified that paternally expressed gene-10 (PEG10) promotes cell cycle progression in the context of TP53 and RB1 loss in neuroendocrine prostate cancer. Based on the evidence that TP53 mutations and RB1 inactivation are more prevalent in muscle invasive bladder cancer (MIBC), it is possible that PEG10 may contribute to the progression and prognosis of MIBC. To test this hypothesis, we characterized PEG10 function in bladder cancer and evaluated if PEG10 can be a novel therapeutic target for these cancers. (Source: The Journal of Urology)



Mp45-03 tailless pten: a potent tumor suppressor in urothelial carcinoma cells

Mon, 28 Mar 2016 19:24:10 +0100

PTEN is a tumor suppressor whose inhibitory activity towards phosphoinositide 3 kinase replies on membrane association, a process that is tightly regulated by electrostatic charges of PTEN tail domain. Precisely how and to what extent this domain affects PTEN’s activity remains unclear and is the subject of the present study. (Source: The Journal of Urology)



Mp45-02 cdoda-me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species

Mon, 28 Mar 2016 19:24:10 +0100

To determine whether CDODA-Me has therapeutic potential in bladder cancer we investigated the effects of CDODA-Me on the growth and survival of bladder cancer cells, and on these cell’s expression of specificity protein (Sp) transcription factors. (Source: The Journal of Urology)



Mp45-01 exosomal mirnas: key regulators of cell-cell communication between bladder cancer cells and tumor microenvironment

Mon, 28 Mar 2016 19:24:10 +0100

Interaction of tumor cells and tumor microenvironment (TME) plays an important role in tumor progression. It was shown that microRNAs (miRNAs) packed in exosomes (EV) can affect cell-cell communication at the site of origin (TME) as well as distant sites. One aim of the project is the identification of a specific miRNA expression pattern from tumor-derived EV of different urinary bladder cancer (UBC) cell lines in correlation to their invasive potential. Afterwards, the functional role of specific exosomal miRNAs on cells of the TME (e.g. (Source: The Journal of Urology)



Mp56-18 health-related quality of life after radical cystectomy: comparative study between orthotopic sigmoid versus ileal neobladders

Mon, 28 Mar 2016 19:24:09 +0100

In recent years, it has been widely accepted that the quality of life (QOL), in addition to cancer control, is an important consideration when determining the therapeutic strategy for patients with malignant tumors. To date, a number of studies have evaluated the postoperative QOL of patients with various types of neobladder (NB), and most of these studies have shown the comparatively favorable QOL of patients with an NB; however, it remains largely unknown which type of NB provides the most favorable postoperative QOL outcomes. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp56-17 recent trends in post-cystectomy health-related quality of life (qol) favours neobladder diversion: systematic review of the literature

Mon, 28 Mar 2016 19:24:09 +0100

The objective of this systematic review is to elucidate whether the current literature indicates that orthotopic neobladder replacement provides better QoL outcomes post-cystectomy than other methods of urinary diversion. (Source: The Journal of Urology)



Mp56-16 radiographic manifestations of pubic symphysis osteomyelitis in the prostate cancer survivor: definitive diagnosis lies in findings on magnetic resonance imaging

Mon, 28 Mar 2016 19:24:09 +0100

Pubic symphysis osteomyelitis (PSO) represents a debilitating complication of radiation and ablative treatments for prostate cancer. The definitive radiographic diagnosis of this is not described. In this review, we characterize the plain film radiographic and magnetic resonance imaging (MRI) findings of PSO in prostate cancer survivors treated at a tertiary referral center providing multidisciplinary treatment for PSO. (Source: The Journal of Urology)



Mp56-15 urodynamic features of pubic symphysis osteomyelitis in the prostate cancer survivor

Mon, 28 Mar 2016 19:24:09 +0100

Pubic symphysis osteomyelitis in the prostate cancer survivor represents a complication of radiation and ablative treatments for prostate cancer, characterized by recurrent pelvic abscess, pubic pain and difficulty with ambulation. Pubic symphysectomy with or without pubic rami debridement, along with concomitant urinary and/or fecal diversion is utilized for long term management of this debilitating condition. In this review we sought to evaluate the urodynamic features of this cohort. (Source: The Journal of Urology)



Mp56-06 complications of continent cutaneous diversions

Mon, 28 Mar 2016 19:24:09 +0100

Continent cutaneous diversion is rarely performed; however, some centers continue to routinely offer patients this form of diversion with excellent functional results. The purpose of this study was to evaluate the short and long term complications of continent cutaneous diversions in patients undergoing radical cystectomy for bladder cancer. (Source: The Journal of Urology)



Mp56-04 the medium term outcomes of stoma formation for patients undergoing conduit diversion for functional aetiology: 5 year follow-up

Mon, 28 Mar 2016 19:24:09 +0100

In this study, we scrutinized the medium-term stomal and para-stomal complications in patients undergoing ileal conduit urinary diversion for functional indications in a tertiary centre. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp63-02 a phase i/ii trial of prehabilitation in patients undergoing cystectomy for bladder cancer

Mon, 28 Mar 2016 19:24:08 +0100

Most cystectomy patients are elderly and frail. As a result, they experience high complication rates, frequent hospital readmissions, poor quality of life (QOL) outcomes and require substantial medical resources. Prehabilitation is the process of fitness training prior to surgery to improve patient outcome. We sought to prospectively study the impact of prehabilitation prior to cystectomy on postoperative readmissions. (Source: The Journal of Urology)



Mp63-01 a proposal for a novel peri-operative mortality risk assessment tool in contemporary patients treated with radical cystectomy

Mon, 28 Mar 2016 19:24:08 +0100

The Charlson comorbidity index (CCI) is the most widely used index score in retrospective analyses. However, several comorbid conditions included in this index, such as sever liver disease, AIDS, leukemia/lymphoma, are never seen in patients candidate to radical cystectomy (RC). Some other comorbid conditions, such as diabetes, and chronic pulmonary disease, are very frequently seen. Conversely, other conditions that are not accounted within that CCI index may represent better predictors of perioperative mortality. (Source: The Journal of Urology)



Pd12-09 characterization of infection risk after radical cystectomy: results from the national surgical quality improvement program

Mon, 28 Mar 2016 19:24:08 +0100

Radical cystectomy (RC) represents the standard of care for muscle-invasive and high-risk non-muscle invasive bladder cancer. However, RC is associated with a high complication rate, including perioperative infection. In addition to causing patient morbidity, infections have been identified as a quality metric. Herein, we evaluated the incidence, risk factors, and timing of infection following RC. (Source: The Journal of Urology)



Pd12-06 urinary diversion for complications of radiation therapy for the treatment of prostate cancer: updated results from the trauma and urologic research network of surgeons

Mon, 28 Mar 2016 19:24:08 +0100

To evaluate surgical outcomes after urinary diversion (UD) for complications of radiation therapy (XRT) for prostate cancer (CaP). (Source: The Journal of Urology)



Mp61-20 primary application study in early diagnosis of bladder cancer by cell-permeable peptides r11

Mon, 28 Mar 2016 19:24:08 +0100

The aim of this study is to investigate the feasibility of cell-permeable peptides R11 conjugated with fluorescein isothiocyanate (FITC-R11) for detecting bladder cancer. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp61-19 concurrent autophagy inhibition potentiates the anti-cancer effects of egfr inhibitor in human bladder cancer cells

Mon, 28 Mar 2016 19:24:08 +0100

Despite the potential therapeutic efficacy of EGFR inhibitors in advanced stage bladder cancer, there are no currently clear evidences yet. Here, we investigate whether combined treatment of EGFR inhibitors and inhibition of autophagy activities exerts the synergistic anti-cancer effects in human bladder cancer cells. (Source: The Journal of Urology)



Mp61-18 a novel formulation of docetaxel with activity in muscle invasive bladder cancer xenografts

Mon, 28 Mar 2016 19:24:08 +0100

Bladder cancer is a significant public health problem responsible for more than 130,000 deaths annually word-wide. Approximately, 70-80% of patients initially present with non-muscle invasive bladder cancer (NMIBC). The rate of recurrence of NMIBC, after standard of care surgery followed by locally administered chemotherapy (mitomycin C, MMC) is 55%. Overall, 30% of patients will ultimately progress toward muscle invasive disease, which is terminal unless treated by radical cystectomy. (Source: The Journal of Urology)



Mp61-17 associations of progression in t1g3 bladder cancers and mutation heterogeneity in 20 cancer-related genes

Mon, 28 Mar 2016 19:24:08 +0100

With about 70-80% non-muscle-invasive bladder cancers (NMIBC) are by far the most common urothelial carcinomas at the time of diagnosis. NMIBC are characterized by a high level of clinical and pathological heterogeneity. Especially high grade NMIBC of stage T1 are prone to progress to an aggressive disease. Therefore, biomarkers to differentiate the progression risk in T1G3 bladder cancers would be greatly beneficial. As muscle-invasive bladder cancers (MIBC) are characterized by mutations, e.g. (Source: The Journal of Urology)



Mp61-16 determination of immune polarization (th1 vs th2) in tumour tissue as a prognostic marker to bcg response in patients with high grade non-muscle invasive bladder cÁncer.

Mon, 28 Mar 2016 19:24:08 +0100

Non muscle invasive bladder cancer represents 70% of all initial bladder cancer diagnosis. The most common method of treatment of NMIBC is transurethral resection of the bladder tumour (TUR) followed by chemotherapy or immunotherapy. Currently BCG immunotherapy administred intravesically is considered the most effective method for preventing recurrence and progression. Intravesicall administration of BCG is hypothesized to act as a localizated Th-1 polarizing immunomodulator that induces massive influx of inflammatory cells. (Source: The Journal of Urology)



Mp61-15 clostridium perfringes enterotoxin as a potential therapeutic for intravesical treatment of bladder cancer

Mon, 28 Mar 2016 19:24:08 +0100

The current intravesical treatment of bladder cancer (BC) is limited to a few chemotherapeutic drugs that shows imperfect effectiveness and are associated with some serious clinical complications. Thus, there is an urgent need for identification of alternative therapies, especially for patients with high-risk non-muscle invasive BC. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp61-14 the impact of neoadjuvant chemotherapy on the timing and site of recurrence following radical cystectomy

Mon, 28 Mar 2016 19:24:08 +0100

Level 1 evidence supports the use of neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) for muscle invasive urothelial bladder cancer (MIBC). Nevertheless, patients may still experience recurrence following NAC+RC. Herein, we sought to evaluate the site-specific recurrence patterns for this population, which have not been previously studied. (Source: The Journal of Urology)



Mp61-13 progranulin targeting in urothelial cancer cells inhibits motility, anchorage-independent growth, tumor formation in vivo and sensitizes cells to cisplatin

Mon, 28 Mar 2016 19:24:08 +0100

Bladder cancer is a major public health problem and affects more than 74,000 Americans with more than 16,000 estimated deaths in 2015. The majority of deaths are due to metastatic spread, commonly to the lungs. Understanding the molecular mechanisms regulating bladder tumor cell invasion and progression toward metastases is essential for developing better therapies to treat bladder cancer patients. The growth factor progranulin has emerged in recent years as an important regulator of transformation in several cancer models. (Source: The Journal of Urology)



Mp61-12 new targets for immune checkpoint inhibition in urothelial carcinoma

Mon, 28 Mar 2016 19:24:08 +0100

Tumor cells evade immune surveillance by expressing cell surface ligands such as PD-L1 that are known to disrupt normal T cell function. Inhibition of these immunologic checkpoints has led to durable clinical remissions in metastatic melanoma, lung cancer, and bladder cancer. Zang et al. have recently described new checkpoint family members (HHLA2 and B7x) that appear to play a significant role in T-cell regulation. We sought to determine whether these newly described ligands are expressed in human urothelial carcinoma. (Source: The Journal of Urology)



Mp61-11 enhanced sensitivity to nvp-bez235 by inhibition of p62/sqstm1 in human bladder cancer kotcc-1 cells both in vitro and in vivo

Mon, 28 Mar 2016 19:24:08 +0100

To date, a number of studies have shown that activation of the cascade mediating mTOR signal transduction may play an important role in the progression of a wide variety of malignant tumors, including bladder cancer. However, several studies have shown the adaptive induction of autophagy by inhibitors of the PI3K/AKT/mTOR pathway, which promotes the survival of cancer cells, resulting in the potential limitation of their own efficacies. Therefore, we herein evaluated changes in the phenotypes of human bladder cancer KoTCC-1 cells both in vitro and in vivo after the RNA interference-mediated knockdown of the p62/SQSTM1 (p62), a multifunctional protein that has been implicated in selective autophagy, with a focus on the antitumor activity of NVP-BEZ235 (NVP), a recently developed dual PI3K/...



Mp61-10 dna methylation inhibitors may reverse drug-resistance in human bladder cancer cells

Mon, 28 Mar 2016 19:24:08 +0100

Aberrant DNA methylation is among common events during tumorigenesis. Although heritable, the dynamic nature and its potential reversibility with pharmacological interventions make it an interesting target for drugs. The aim of this study was to evaluate the chemotherapeutic re-sensitivity of cisplatin (CDDP) and gemcitabine (GEM) resistance in bladder cancer cell lines induced by the hypomethylating agent 5-aza-2-deoxycytidine (5-Aza-CdR). (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp61-09 early development of intravesical reflectance spectroscopy for bladder tumor detection and staging

Mon, 28 Mar 2016 19:24:08 +0100

The objective of this study is to develop the potential of single-fiber reflectance spectroscopy (SfRS) to discriminate neoplastic bladder tissue from normal tissue. (Source: The Journal of Urology)



Mp61-08 photothermal ablation of bladder cancer using phosphatidylserine targeted carbon nanotubes

Mon, 28 Mar 2016 19:24:08 +0100

Use of ablative therapy has the potential to treat bladder cancer resistant to BCG and chemotherapy. However, early efforts with photodynamic therapy and intravenous application of the photosensitizer resulted in significant complications. We have combined Annexin V targeting of phosphatidylserine on tumor surface with single-walled carbon nanotubes (SWNTs) to target bladder tumor cells and treat with near infrared (NIR) light for thermal ablation of tumor in the preclinical setting. (Source: The Journal of Urology)



Mp61-07 the effect of levofloxacin on bacillus calmette-guerin induced toxicity in patients with nonmuscle-invasive bladder cancer: results of a randomized, prospective, multicenter study.

Mon, 28 Mar 2016 19:24:08 +0100

Although bacillus Calmette-Guerin (BCG) is a standard of care for high-risk nonmuscle invasive bladder cancer (NMIBC) patients, the high rate of adverse events (AEs) remains a major problem. In this randomized, prospective, multicenter study, we examined whether levofloxacin (LVFX) administered after each intravesical instillation of BCG could improve its tolerance in patients with intermediate to high-risk urothelial carcinoma of the bladder. We also investigated the impact of LVFX on the antitumor activity of BCG. (Source: The Journal of Urology)



Mp61-06 photodynamic therapy for non-muscle invasive bladder cancer mediated by instilled photosensitizer tld1433 and green light activation

Mon, 28 Mar 2016 19:24:08 +0100

Bladder cancer is the most common malignant tumor in the urinary tract and accounts for 3.3% of all cancers. An estimated 72,570 new bladder cancer cases occurred in the US in 2013 and resulted in approximately 15,210 deaths. Transurethral resection of a bladder tumor is the standard first line treatment. Although effective at treating the tumor, the recurrence rate ranges from 60% to 70%. Photodynamic therapy (PDT), where a photosensitizer (PS) converts light into cytotoxic radical oxygen species to cause cell death, was initially approved for bladder cancer in 1993. (Source: The Journal of Urology)